Rich Getto has spent his 25-year biotech career working to deliver CMC efficiencies that translate to increased patient access to therapies. He is currently the Senior Vice President of Portfolio Strategy & Product Delivery at BrainChild Bio where he leads the Program Management, CMC Development, and Patient Operations teams. Prior to joining BrainChild Bio, Rich was the Senior Vice President of Program Management and Portfolio Strategy of Umoja Biopharma and built multiple functions as the company grew toward delivering in vivo CAR T to the clinic. Rich joined the world of CAR T therapy as an early employee of Juno Therapeutics, serving multiple roles at the company for 6 years, including leading the evaluation and development of advanced analytical and manufacturing technologies with the goal of significantly driving down the costs of manufacturing autologous CAR T products culminating in the development of the NEX-TTM platform. In the pre-cell therapy portion of his career, he was the Global Network Leader of Amgen’s tech transfer process where he oversaw more than 100 tech transfers across Amgen’s internal and external manufacturing network while decreasing transfer timelines and costs and simultaneously increasing success rates. Rich holds a BS in Chemical Engineering from Montana State University, an MS in Biotechnology from the Technische Universität Hamburg-Harburg, and an MBA from the Northern Institute of Technology in Hamburg, Germany. He served 3 years as a board member of Strawberry Theatre Workshop and is currently an advisory board member of Holy Mountain Brewing Company.